These findings suggest that targeting the RAR-β/MLC-2 axis could be a compelling strategy to impair cancer metastasis, and positions this pathway as an important player in therapies aimed at mechanically modulating the tumour and its microenvironment. The gene discussed is MYL9; the disease is neoplasm.